Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials

BACKGROUND: Pandemic influenza vaccine manufacturing capacity and distribution agility is enhanced through the availability of equivalent antigen-sparing vaccines. We evaluated equivalence in terms of immunogenicity between GlaxoSmithKline Vaccines’ A/California/7/2009 (H1N1)v-like-AS03 vaccines man...

Descripción completa

Detalles Bibliográficos
Autores principales: Launay, Odile, Duval, Xavier, Fitoussi, Serge, Jilg, Wolfgang, Kerdpanich, Angkool, Montellano, May, Schwarz, Tino F, Watanveerade, Veerachai, Wenzel, Jürgen J, Zalcman, Gerard, Bambure, Vinod, Li, Ping, Caplanusi, Adrian, Madan, Anuradha, Gillard, Paul, Vaughn, David W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848562/
https://www.ncbi.nlm.nih.gov/pubmed/24041010
http://dx.doi.org/10.1186/1471-2334-13-435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848562/
https://www.ncbi.nlm.nih.gov/pubmed/24041010
http://dx.doi.org/10.1186/1471-2334-13-435

Ejemplares similares